Evidence map›Paper›PMID 29121929›Full record

ArticleMalaria journal2017

Variation in the immune responses against Plasmodium falciparum merozoite surface protein-1 and apical membrane antigen-1 in children residing in the different epidemiological strata of malaria in Cameroon.

Tebit Emmanuel Kwenti, Adzemye Linus Moye, Adzemye Basil Wiylanyuy, Longdoh Anna Njunda, Theresa Nkuo-Akenji

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Genetic Diversity ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  2. Serology reveals comparable patterns in the transmission intensities ofFrontiers in cellular and infection microbiology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in microbiology · 2019
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tebit Emmanuel KwentiDepartment of Microbiology and Parasitology, University of Buea, P.B. 63, Buea, Cameroon. kwentitebit@yahoo.com.
Adzemye Linus MoyeDistrict Hospital of Cite Verte, P.B. 3604, Yaounde, Cameroon.
Adzemye Basil WiylanyuyDistrict Hospital of Mbengwi, Mbengwi, North West Region, Cameroon.
Longdoh Anna NjundaDepartment of Microbiology and Parasitology, University of Buea, P.B. 63, Buea, Cameroon.
Theresa Nkuo-AkenjiDepartment of Microbiology and Parasitology, University of Buea, P.B. 63, Buea, Cameroon.
University of Buea · CMUniversity Teaching Hospital of Yaounde · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies to assess the immune responses against malaria in Cameroonian children are limited. The purpose of this study was to assess the immune responses against Plasmodium falciparum merozoite surface protein-1 (MSP-1

methodsIn a cross-sectional survey performed between April and July 2015, 602 children between 2 and 15 years (mean ± SD = 5.7 ± 3.7), comprising 319 (53%) males were enrolled from five epidemiological strata of malaria in Cameroon including: the sudano-sahelian (SS) strata, the high inland plateau (HIP) strata, the south Cameroonian equatorial forest (SCEF) strata, the high western plateau (HWP) strata, and the coastal (C) strata. The children were screened for clinical malaria (defined by malaria parasitaemia ≥ 5000 parasites/µl plus axillary temperature ≥ 37.5 °C). Their antibody responses were measured against P. falciparum MSP-1

resultsA majority of the participants were IgG responders 72.1% (95% CI 68.3-75.6). The proportion of responders was higher in females (p = 0.002) and in children aged 10 years and above (p = 0.005). The proportion of responders was highest in Limbe (C strata) and lowest in Ngaoundere (HIP strata) (p < 0.0001). Similarly, the mean IgG antibody levels were higher in children aged 10 years and above (p < 0.0001) and in Limbe (p = 0.001). The IgG antibody levels against AMA-1 were higher in females (p = 0.028), meanwhile no gender disparity was observed with MSP-1. Furthermore the risk of clinical malaria (p < 0.0001) and the mean parasite density (p = 0.035) were higher in IgG non-responders.

conclusionA high proportion of IgG responders was observed in this study, suggesting a high degree exposure of the target population to malaria parasites. The immune responses varied considerably across the different strata: the highest levels observed in the C strata and the lowest in the HIP strata. Furthermore, malaria transmission in Cameroon could be categorized into two major groups based on the serological reaction of the children: the southern (comprising C and SCEF strata) and northern (comprising HWP, HIP and SS strata) groups. These findings may have significant implications in the design of future trials for evaluating malaria vaccine candidates in Cameroon.

Indexed as

Immunity, HumoralAdolescentAntigens, ProtozoanCameroonChildChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GMalariaMaleMembrane ProteinsMerozoite Surface Protein 1Plasmodium falciparumProtozoan ProteinsAntigens, Protozoanapical membrane antigen I, PlasmodiumImmunoglobulin GMembrane ProteinsMerozoite Surface Protein 1Protozoan ProteinsApical membrane antigen-1CameroonChildrenELISAEpidemiological strataMalaria immune responsesMerozoite surface protein-1Plasmodium falciparum

Identifiers

PMID29121929
PMCPMC5679504
OpenAlexW2767660681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.